Biopsy Method and Excision Volume Do Not Affect Success Rate of Subsequent Sentinel Lymph Node Dissection in Breast Cancer

Haigh, Philip I.; Hansen, Nora M.; Qi, Karen; Giuliano, Armando E.

doi:10.1007/s10434-000-0021-1

Cited by 129 publications

(57 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite varying lymphatic mapping techniques used worldwide, identification rates remain consistently higher than 91%, with false negatives estimated at 8% 4 ; with more extensive experience, these rates approach 100% [5][6][7] and <5%, 7,8 respectively. A pathologically negative SLN is now widely accepted as reliably identifying the node-negative breast cancer patient who does not need to face the morbidity of a standard ALND.…”

mentioning

confidence: 98%

Comprehensive Axillary Evaluation in Neoadjuvant Chemotherapy Patients With Ultrasonography and Sentinel Lymph Node Biopsy

et al. 2005

View full text Add to dashboard Cite

Background: There is ongoing debate regarding the optimal sequence of sentinel lymph node (SLN) biopsy and neoadjuvant chemotherapy (CTX) for breast cancer. We report the accuracy of comprehensive pre-neoadjuvant CTX and post-neoadjuvant CTX axillary staging via ultrasound imaging, fine-needle aspiration (FNA) biopsy, and SLN biopsy. Results: Axillary staging was pathologically negative by pre-neoadjuvant CTX SLN biopsy in 53 cases (58%); these patients had no further axillary surgery. In 38 cases (42%), axillary metastases were confirmed at presentation by either ultrasound-guided FNA or SLN biopsy. These 38 patients underwent completion axillary lymph node dissection (ALND) after delivery of neoadjuvant CTX. Follow-up lymphatic mapping was attempted in 33 of these cases, and the SLN was identified in 32 (identification rate, 97%). One third of these cases were completely node negative on ALND. Residual metastatic disease was identified in 22 cases, and the SLN was falsely negative in 1 (4.5%).Conclusions: Patients receiving neoadjuvant CTX can have accurate axillary nodal staging by ultrasound-guided FNA or SLN biopsy. In cases of documented axillary metastasis at presentation, repeat axillary staging with SLN biopsy can document the post-neoadjuvant CTX nodal status. This strategy optimizes pre-neoadjuvant CTX and post-neoadjuvant CTX staging information by distinguishing the patients who are node negative at presentation from those who have been downstaged to node negativity and offers the potential for avoiding unnecessary ALNDs in both of these patient subsets.

show abstract

mentioning

confidence: 98%

Comprehensive Axillary Evaluation in Neoadjuvant Chemotherapy Patients With Ultrasonography and Sentinel Lymph Node Biopsy

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Primer tümörün çapı arttıkça aksilladaki metastatik lenf nodu sayısının arttığı bildirilmiştir [20]. Bir çalışmada tümör çapı 3cm'nin altındaki tümörlerde aksillaya metastaz oranı %38 olarak bulunurken, 3-5cm arasındaki tümörlerde bu oran %55 olarak bulunmuştur [21][22][23].…”

Section: Discussionunclassified

Meme kanserinde sentinel lenf nodu uygulaması: 30 vakanın analizi

Köse

Erdem

2017

Archives of Clinical and Experimental Medicine

View full text Add to dashboard Cite

Results: Sentinel lymph node involvement was detected in 14 (46.7%) of 30 patients. In the other 16 patients (53.3%), no involvement of the sentinel lymph nodes was detected and six of these patients (37.5%) did not undergo axillary dissection. None of the nine patients (56.2%) without sentinel lymph node involvement had also no axillary involvement. Axillary involvement was detected only in one patient. In our study, 10 patients (62.5%) who had no sentinel lymph node involvement but had axillary dissection showed false negativity in one patient and it was seen that this patient was the first patient to be included in the study. Sentinel lymph node detection rate was 88.2%, accuracy rate was 76.6%, sensitivity rate was 88.2% and false negative rate was 10%. Conclusion: The use of sentinel lymph node biopsy in the surgical treatment of breast cancer is a safe approach.

show abstract

“…[33][34][35] Recently, Haigh et al demonstrated that a previous excisional biopsy did not compromise successful identification of the sentinel lymph node. 53 Although the therapeutic perspectives for the ABBI method are limited at present by the small number of potential indications and the need for axillary lymph node staging for invasive lesions, this procedure may have a contributory role within the framework of the management of subclinical cancers. Stereotactic large-core breast biopsy, which is currently used to diagnose NPBL, provide fragmented tissue specimens and almost total disappearance of the tumor, when it is small.…”

Section: Discussionmentioning

confidence: 99%

Percutaneous stereotactic en bloc excision of nonpalpable breast carcinoma: a step in the direction of supraconservative surgery

Lifrange¹,

Dondelinger²,

Foidart³

et al. 2002

The Breast

View full text Add to dashboard Cite

SUMMARYRecently, the advanced breast biopsy instrumentation (ABBI) system has been introduced as an alternative to conventional breast biopsy techniques. This study was prospectively conducted to evaluate the potential of the ABBI method in locoregional management of a consecutive series of patients with nonpalpable mammographically detected breast carcinomas. Sixty-one consecutive patients underwent an ABBI procedure as a first step before possible surgery for nonpalpable breast lesions that would in any case require complete excision. For the 27 patients in whom the ABBI biopsy revealed malignancy further surgery was recommended, including re-excision of the biopsy site and axillary dissection in cases of infiltrating carcinoma. We calculated the probabilities that the ABBI specimen would have tumor-free margins and that a definitely complete excision had been achieved as a function of the mammographic or pathological diameter of the cancer. For cancer with a pathological diameter less than 10 mm measured on the ABBI specimen, the probability (92%) of obtaining complete resection was significantly better than for larger lesions (P = 0.01, Fisher's exact test). Although the therapeutic perspectives for the ABBI method are limited at present, we suggest that this approach is a first step in the direction of a surgical strategy that is better adapted to the pathological characteristics peculiar to these small tumors, whose incidence is increasing.

show abstract

Biopsy Method and Excision Volume Do Not Affect Success Rate of Subsequent Sentinel Lymph Node Dissection in Breast Cancer

Cited by 129 publications

References 21 publications

Comprehensive Axillary Evaluation in Neoadjuvant Chemotherapy Patients With Ultrasonography and Sentinel Lymph Node Biopsy

Comprehensive Axillary Evaluation in Neoadjuvant Chemotherapy Patients With Ultrasonography and Sentinel Lymph Node Biopsy

Meme kanserinde sentinel lenf nodu uygulaması: 30 vakanın analizi

Percutaneous stereotactic en bloc excision of nonpalpable breast carcinoma: a step in the direction of supraconservative surgery

Contact Info

Product

Resources

About